The olfaction intellectual property assets that we hold primarily consist of an exclusive worldwide license issued by The Trustees of Columbia University in the City of New York (“Columbia”), as described in more detail below under the heading “Licensed Products and Services” (the “Columbia License”), and certain issued patents and patent applications titled “Nucleic Acids and Proteins of Insect or 83b odorant receptor genes and uses thereof.” The olfaction intellectual property assets are also referred to in this Form 10-K as “our olfaction intellectual property.” Primarily due to the estimated revenues to be earned under the Bayer Agreement described below under the heading “Agreement with Bayer CropScience AG”, entered into during the current period, management has determined that the Company has commenced its planned principal operations and is no longer considered a development stage company as of September 15, 2010. We have a limited operating history. We have generated only limited revenues from operations. All losses accumulated since the commencement of our business have been considered as part of our development stage activities.
Company profile
Ticker
SSRC
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
205655648
Latest filings (excl ownership)
15-12G
Securities registration termination
28 Mar 12
8-K
Other Events
13 Mar 12
10-Q
2011 Q3
Quarterly report
14 Nov 11
10-Q
2011 Q2
Quarterly report
15 Aug 11
8-K
Submission of Matters to a Vote of Security Holders
9 Aug 11
CT ORDER
Confidential treatment order
28 Jun 11
DEF 14A
Definitive proxy
28 Jun 11
PRE 14A
Preliminary proxy
9 Jun 11
10-Q
2011 Q1
Quarterly report
16 May 11
8-K
Entry into a Material Definitive Agreement
25 Apr 11
Latest ownership filings